{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:29:34Z","timestamp":1792301374256,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"13","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.vaccine.2015.01.084","type":"journal-article","created":{"date-parts":[[2015,2,11]],"date-time":"2015-02-11T23:17:16Z","timestamp":1423696636000},"page":"1608-1613","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":106,"title":["Reduction in HPV 16\/18-associated high grade cervical lesions following HPV vaccine introduction in the United States \u2013 2008\u20132012"],"prefix":"10.1016","volume":"33","author":[{"given":"Susan","family":"Hariri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Niccolai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Schafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina U.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen C.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth R.","family":"Unger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Whitney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"Julian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary W.","family":"Scahill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasreen","family":"Abdullah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle L.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Steinau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauri E.","family":"Markowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 3","key":"10.1016\/j.vaccine.2015.01.084_bib0130","article-title":"Chapter 1: HPV in the etiology of human cancer","volume":"24","author":"Munoz","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0135","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1097\/EDE.0b013e3181afede2","article-title":"Epidemiology's contributions to a Nobel Prize recognition","volume":"20","author":"Franco","year":"2009","journal-title":"Epidemiology"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0140","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1470-2045(10)70230-8","article-title":"Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study","volume":"11","author":"de Sanjose","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0145","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agents Cancer"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0150","doi-asserted-by":"crossref","first-page":"c3493","DOI":"10.1136\/bmj.c3493","article-title":"Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial","volume":"341","author":"FUTURE I\/II Study Group","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0155","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0160","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jadohealth.2013.09.018","article-title":"Population impact of HPV vaccines: summary of early evidence","volume":"53","author":"Hariri","year":"2013","journal-title":"J Adolesc Health"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0165","doi-asserted-by":"crossref","first-page":"djt460","DOI":"10.1093\/jnci\/djt460","article-title":"Early impact of human papillomavirus vaccination on cervical neoplasia \u2013 nationwide follow-up of young Danish women","volume":"106","author":"Baldur-Felskov","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0170","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0175","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1038\/bjc.2014.479","article-title":"Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland","volume":"111","author":"Pollock","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0180","doi-asserted-by":"crossref","first-page":"g1458","DOI":"10.1136\/bmj.g1458","article-title":"Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia","volume":"348","author":"Crowe","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0185","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s10552-014-0392-4","article-title":"Incidence of cervical lesions in Danish women before and after implementation of a national HPV vaccination program","volume":"25","author":"Baldur-Felskov","year":"2014","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0190","first-page":"626","article-title":"FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Centers for Disease Control and Prevention","year":"2010","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0195","first-page":"620","article-title":"Human papillomavirus vaccination coverage among adolescents, 2007\u20132013, and postlicensure vaccine safety monitoring, 2006\u20132014 \u2013 United States","volume":"63","author":"Stokley","year":"2014","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0200","first-page":"625","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2013","volume":"63","author":"Elam-Evans","year":"2014","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0205","first-page":"66","article-title":"Noninfluenza vaccination coverage among adults \u2013 United States, 2011","volume":"62","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0210","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/infdis\/jit192","article-title":"Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003\u20132010","volume":"208","author":"Markowitz","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0215","first-page":"1038","article-title":"Cervical cancer screening among women aged 18\u201330 years \u2013 United States, 2000\u20132010","volume":"61","author":"Centers for Disease Control and Prevention","year":"2013","journal-title":"MMWR"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0220","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S0140-6736(07)61416-0","article-title":"Human papillomavirus and cervical cancer","volume":"370","author":"Schiffman","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10552-011-9877-6","article-title":"The HPV vaccine impact monitoring project (HPV-IMPACT): assessing early evidence of vaccination impact on HPV-associated cervical cancer precursor lesions","volume":"23","author":"Hariri","year":"2012","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0230","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJM198009043031003","article-title":"Pneumococcal disease after pneumococcal vaccination: an alternative method to estimate the efficacy of pneumococcal vaccine","volume":"303","author":"Broome","year":"1980","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0235","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2105\/AJPH.2012.301182","article-title":"Prevalence of anogenital warts among participants in private health plans in the United States, 2003\u20132010: potential impact of human papillomavirus vaccination","volume":"103","author":"Flagg","year":"2013","journal-title":"Am J Public Health"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0240","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.vaccine.2012.10.092","article-title":"Impact of human papillomavirus (HPV) vaccination on HPV 16\/18-related prevalence in precancerous cervical lesions","volume":"31","author":"Powell","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.01.084_bib0250","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1086\/597307","article-title":"The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16\u201326 years","volume":"199","author":"Brown","year":"2009","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,25]],"date-time":"2018-09-25T08:25:42Z","timestamp":1537863942000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":24,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0264410X15001516"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.084","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduction in HPV 16\/18-associated high grade cervical lesions following HPV vaccine introduction in the United States \u2013 2008\u20132012","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.01.084","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}